O ur recent study showed that donor-specific HLA antibodies (DSAs) were common after pediatric liver transplantation (LT). 1 The aim was to conduct a meta-analysis of DSA prevalence after pediatric LT.
with the method by DerSimonian and Laird was used. The average prevalence estimate across the studies is obtained under the random-effects model. In addition, 95% prediction interval (PI) was calculated to obtain a predicted range of true DSA prevalence for a new analogous study. The details of PI have been described elsewhere. 3 Literature search yielded 28 references of which 8 were included in the analysis. One study missed in the aforementioned search was included based on an earlier knowledge of its existence (total of 9 studies). Reasons for exclusion were mixed population (n = 5), intestinal transplantation (n = 5), case reports (n = 3), review (n = 2), editorial (n = 1), DSAs evaluated only prior LT (n = 1), overlapping study population (n = 1), patients not on immunosuppression (n = 1), and full text not available (n = 1). Some of the studies had multiple reasons for exclusion.
Age at the time of LT varied between studies ( Table 1) . Two of the studies included patients not on immunosuppression at the time of DSAs (Table 1 footnote).
Total sample size was 322 patients (Figure 1 ). Average prevalence of DSAs was 41% (95% CI, 29%-54%) although prevalence varied across studies as evident with the heterogeneity statistics (I 2 = 77% [95% CI, 56%-88%], P < 0.001 for heterogeneity). The PI indicated that the true DSA prevalence for a new analogous study will fall 95% of times within interval of 11% to 80%.
There was little influence on heterogeneity when omitting 1 study at the time. The largest impact on heterogeneity was observed after excluding study by Waki et al 4 (I 2 from 77% to 66%) or study by Markiewicz-Kijewska et al 5 (I 2 from 77% to 71%). Average DSA prevalence was 51% (95% CI, 43%-58%) after excluding these 2 studies simultaneously. Heterogeneity also diminished (I 2 = 29% [95% CI, 0%-69%], P = 0.207), and the PI also became narrower as expected (34% to 67%). The other excluded study evaluated DSAs shortly after LT (at 3 weeks). 4 This study has limitations. First, only 1 author extracted the data which can bias the extraction process. Second, the literature search was simple and based only on 1 database. Third, the impact of different study characteristics on heterogeneity was not assessed.
These limitations in mind, the average DSA prevalence was 41% (95% CI, 29%-54%) across 9 studies after pediatric LT although variability between studies was noticeable. DDLT, deceased donor liver transplantation; DSA, donor-specific antibody; LDLT, living donor liver transplantation; MFI, mean fluorescence intensity; OT, operational tolerant. FIGURE 1. Average (95% CI) prevalence of 41% (29% to 54%) (grey diamond) for DSAs after pediatric LT. I 2 is shown with 95% CI. I 2 depicts that 77% of variability in DSA prevalence estimates across studies is beyond sampling error (ie, due to heterogeneity). CIs for individual studies were calculated with the method by Clopper-Pearson. Between-study variance (τ 2 ) was estimated with the method by DerSimonian and Laird. The prediction interval (black solid line) refers to a predicted interval of true DSA prevalence for a new analogous study.
